CRBP Logo

Corbus Pharmaceuticals Holdings, Inc. (CRBP) 

NASDAQ
Market Cap
$158.33M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
8 of 960
Rank in Industry
6 of 550

Largest Insider Buys in Sector

CRBP Stock Price History Chart

CRBP Stock Performance

About Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the …

Insider Activity of Corbus Pharmaceuticals Holdings, Inc.

Over the last 12 months, insiders at Corbus Pharmaceuticals Holdings, Inc. have bought $53.69M and sold $1.89M worth of Corbus Pharmaceuticals Holdings, Inc. stock.

On average, over the past 5 years, insiders at Corbus Pharmaceuticals Holdings, Inc. have bought $17.94M and sold $723,889 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Cormorant Asset Management, LP (10 percent owner) — $912.79M.

The last purchase of 350,000 shares for transaction amount of $7M was made by Cormorant Asset Management, LP (10 percent owner) on 2024‑09‑20.

List of Insider Buy and Sell Transactions, Corbus Pharmaceuticals Holdings, Inc.

2024-09-20Purchase10 percent owner
350,000
3.227%
$20.01$7M-8.61%
2024-06-18SaleChief Executive Officer
9,501
0.1849%
$42.24$401,294-3.04%
2024-06-18SaleChief Financial Officer
1,958
0.038%
$42.12$82,479-3.04%
2024-06-17SaleChief Executive Officer
1,770
0.0375%
$46.02$81,456-3.70%
2024-06-17SaleChief Financial Officer
6,730
0.145%
$46.77$314,789-3.70%
2024-06-14SaleChief Executive Officer
12,487
0.2886%
$50.17$626,425-14.83%
2024-06-14SaleChief Financial Officer
7,788
0.179%
$49.87$388,417-14.83%
2024-03-08Purchase10 percent owner
300,000
6.1345%
$44.38$13.31M-7.63%
2024-03-07Purchase10 percent owner
250,000
4.6136%
$40.05$10.01M+3.08%
2024-02-02Purchase10 percent owner
750,000
6.5656%
$19.00$14.25M+46.59%
2024-01-26Purchase10 percent owner
282,632
4.1983%
$32.24$9.11M+31.55%
2022-08-10PurchaseChief Financial Officer
20,000
0.0024%
$0.26$5,198-23.53%
2022-08-10PurchaseChief Executive Officer
3,800
0.0005%
$0.26$1,003-23.53%
2022-08-10PurchaseChief Operating Officer
5,000
0.0006%
$0.25$1,273-23.53%
2022-05-16PurchaseChief Financial Officer
12,000
0.0017%
$0.30$3,600-34.56%
2022-05-16PurchaseChief Executive Officer
10,500
0.0012%
$0.25$2,625-34.56%
2022-03-10PurchaseChief Financial Officer
15,000
0.0026%
$0.37$5,550-46.84%
2022-03-10PurchaseChief Operating Officer
10,000
0.0017%
$0.37$3,700-46.84%
2022-03-09PurchaseChief Executive Officer
8,600
0.0015%
$0.37$3,182-44.14%
2020-12-21SaleChief Financial Officer
87,500
0.0706%
$1.75$153,125-0.66%

Insider Historical Profitability

13.23%
Cormorant Asset Management, LP10 percent owner
2375000
19.5%
$13.0050
Cohen YuvalChief Executive Officer
77221
0.634%
$13.00253+10.48%
Moran Sean F.Chief Financial Officer
48605
0.3991%
$13.00456+30.87%
Tepper MarkPresident and CSO
2101000
17.2503%
$13.0010
White BarbaraChief Medical Officer
206217
1.6931%
$13.00270+9.31%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.